Literature DB >> 10678561

Surgical management of primary lung cancer in an elderly patient with preoperative empyema.

M Harada1, J Yoshida, T Yokose, Y Nishiwaki, K Nagai.   

Abstract

A 74-year-old man with primary lung cancer developed preoperative empyema but was successfully managed surgically. The patient was given a diagnosis of c-T2N1M0, stage IIB, moderately differentiated squamous cell carcinoma, but before surgery pneumothorax and empyema developed, resulting from rupture of the carcinoma. Thoracic drainage, lavage and systemic administration of antibiotics improved his empyema. As there were no malignant cells in the drainage fluid, right middle-lower bilobectomy, empyemal cavity resection and lymph node dissection were performed. The bronchial stump was covered with an intercostal muscle flap. Thoracic drainage, lavage and systemic administration of antibiotics were performed for 6 days following the operation. The patient was discharged on the 27th postoperative day without any complications having developed. The pathological diagnosis of the tumor was p-T4N2(#7)M0, stage IIIB, br(-), ly(+), v(+), p3(pleura), pm1 and d0. He died of recurrence at home 18 months after the operation. We believe the following to be the minimum requirements for surgical management of such patients: (1) immediate thoracic cavity drainage and lavage with systemic antibiotic therapy, aiming at infection control before surgery; (2) prophylactic lavage of the thoracic cavity during and after surgery and (3) coverage of the bronchial stump with an adequate flap. Six reported cases of primary lung cancer with preoperative empyema are also discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10678561     DOI: 10.1093/jjco/29.11.571

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  1 in total

1.  Metastatic Lung Cancer Presenting as Thoracic Empyema in an Old Patient.

Authors:  Y-M Tsai; Yu-C Lin; T-W Huang; H Chang
Journal:  West Indian Med J       Date:  2014-06-20       Impact factor: 0.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.